News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunetrics, Inc. And Eli Lilly and Company (LLY) To Apply In Silico Modeling Technology To Trial Design


10/19/2005 5:09:14 PM

PITTSBURGH, Sept. 7 /PRNewswire/ -- Immunetrics Inc. said it entered into an agreement under which it will collaborate with Eli Lilly & Co. in the application of in silico modeling technology to clinical trial design.

The specific application, which was not disclosed, involves the adaptation of existing Immunetrics models of inflammation for the identification of novel biomarkers and the development of design parameters for relevant human studies.

"We're thrilled to apply this technology to a specific development project at Lilly," said Steven Chang, CEO of Pittsburgh-based Immunetrics. "Our ability to simulate a complex clinical question will be augmented by the extensive clinical and biochemical data repositories available from Lilly."

The collaboration represents an additional demonstration of interest by the pharmaceutical industry in using modeling approaches to supplement statistical analysis in study design. Critical Care Medicine has previously called in silico modeling "a method coming of age," enabling investigators to optimize trial design outcomes by modeling an extremely large number of possible trials involving a large number of variables.

Immunetrics has demonstrated the utility of dynamical models in experimental design of a number of complex clinical settings, including trauma, hemorrhage, shock, sepsis, coronary artery bypass and acute respiratory distress syndrome. The company is also developing models of use in cancer immunology and in the prediction of adverse drug reactions in chronic inflammation.

About Immunetrics Inc.

Immunetrics is a Pittsburgh-based biosimulation company providing a platform to model complex biological systems. Immunetrics possesses the first known comprehensive model of the acute inflammatory response, which is now enhanced with key elements of the adaptive immune system and coagulation cascade. With this model, Immunetrics can help drug companies prioritize and design preclinical and clinical programs for new therapies. Immunetrics was founded by LaunchCyte LLC and has been funded by Innovation Works, the University of Pittsburgh Medical Center, the University of Pittsburgh, the Pittsburgh Life Sciences Greenhouse, and individual investors.

About the Pittsburgh Life Sciences Greenhouse (PLSG) Incubator

Immunetrics Inc. is located in the PLSG Incubator. The PLSG Incubator is co-located with the PLSG administrative and support functions, which together occupy 17,000 square feet of space on the fourth floor of Bridgeside Point, better known as the Cellomics Building on Technology Drive in Pittsburgh. Incubator facilities consist of 40 percent lab and 60 percent office space and houses 16 life sciences organizations, which also have convenient access to other services programs offered by the PLSG.

Pittsburgh Life Sciences Greenhouse

CONTACT: Steven Chang, Chief Executive Officer of Immunetrics Inc.,+1-412-770-1311, or steve@immunetrics.com


Read at Bioinformatics


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES